ArticleEuropean urology2019
Inflammatory Bowel Disease and the Risk of Prostate Cancer.
Article in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis.Cancers · 2025Pooled it
- Association between inflammatory bowel disease and risk of incident prostate cancer: a systematic review and meta-analysis of cohort studies.International journal of colorectal disease · 2023Pooled it
- Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2020Pooled it
- The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis.Prostate cancer and prostatic diseases · 2020Pooled it
- Gut Microbiome as a Lifestyle Risk Factor Associated with Prostate Cancer.European urology focus · 2026Article
- Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study.World journal of urology · 2026Article
- Inflammatory bowel disease and prostate cancer: from epidemiological controversy to mechanistic hypotheses.Frontiers in immunology · 2026Review
- Case Report: Chronic Prostatitis as an Extraintestinal Manifestation of Ulcerative Colitis.IJU case reports · 2025Article
- Endocrine-disrupting chemicals as prostate carcinogens.Nature reviews. Urology · 2025Review
- Identification of an intestinal microbiota enterotypes in ageing man diagnosed with benign prostatic hyperplasia (BPH).Scientific reports · 2025Article
- Plant-derived extracellular vesicles: an alternative and complementary therapeutic approach for genitourinary tumors.Frontiers in cell and developmental biology · 2025Review
- A hematological and inflammatory marker-based model for prostate carcinoma diagnosis.American journal of cancer research · 2025Article
- Understanding and overcoming resistance to immunotherapy in genitourinary cancers.Cancer biology & therapy · 2024Review
- Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer.Human cell · 2024Article
- Association between autoimmunity-related disorders and prostate cancer: A Mendelian randomization study.Cancer pathogenesis and therapy · 2024Article
- The association between inflammatory bowel disease and risk of prostate cancer: a population-based retrospective study based on Korean National Health Insurance Service database.Prostate international · 2024Article
- Phase 1 clinical trial evaluating safety, bioavailability, and gut microbiome with a combination of curcumin and ursolic acid in lipid enhanced capsules.Journal of traditional and complementary medicine · 2024Article
- Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review.Life (Basel, Switzerland) · 2024Review
- Risk relationship between inflammatory bowel disease and urolithiasis: A two-sample Mendelian randomization study.PloS one · 2024Article
- The potential role of the microbiota in prostate cancer pathogenesis and treatment.Nature reviews. Urology · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThere are limited data examining the risk of prostate cancer (PCa) in patients with inflammatory bowel disease (IBD).
objectiveTo compare the incidence of PCa between men with and those without IBD. DESIGN, SETTING, AND
participantsThis was a retrospective, matched-cohort study involving a single academic medical center and conducted from 1996 to 2017. Male patients with IBD (cases=1033) were randomly matched 1:9 by age and race to men without IBD (controls=9306). All patients had undergone at least one prostate-specific antigen (PSA) screening test. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier and multivariable Cox proportional hazard models, stratified by age and race, evaluated the relationship between IBD and the incidence of any PCa and clinically significant PCa (Gleason grade group ≥2). A mixed-effect regression model assessed the association of IBD with PSA level. RESULTS AND LIMITATIONS: PCa incidence at 10yr was 4.4% among men with IBD and 0.65% among controls (hazard ratio [HR] 4.84 [3.34-7.02] [3.19-6.69], p<0.001). Clinically significant PCa incidence at 10yr was 2.4% for men with IBD and 0.42% for controls (HR 4.04 [2.52-6.48], p<0.001). After approximately age 60, PSA values were higher among patients with IBD (fixed-effect interaction of age and patient group: p=0.004). Results are limited by the retrospective nature of the analysis and lack of external validity.
conclusionsMen with IBD had higher rates of clinically significant PCa when compared with age- and race-matched controls. PATIENT SUMMARY: This study of over 10000 men treated at a large medical center suggests that men with inflammatory bowel disease may be at a higher risk of prostate cancer than the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.